Login to Your Account

Paion Shares Soar as Lundbeck Buys Stroke Drug Desmoteplase

By Cormac Sheridan
Staff Writer

Wednesday, February 29, 2012
Shares in struggling German drug developer Paion AG soared by more than 30 percent Tuesday on news that its partner, Lundbeck A/S, was handing it a financial lifeline by agreeing to pay €20.1 million (US$27 million) to acquire all outstanding rights to its Phase III stroke drug desmoteplase.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription